Page last updated: 2024-10-22

am 251 and Depressive Disorder, Major

am 251 has been researched along with Depressive Disorder, Major in 2 studies

AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research Excerpts

ExcerptRelevanceReference
"Stress contributes to major depressive disorder (MDD) and chronic pain, which affect a significant portion of the global population, but researchers have not clearly determined how these conditions are initiated or amplified by stress."1.62mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress. ( Han, J; Huang, M; Luo, L; Ma, X; Shi, H; Su, C; Wang, A; Wang, H; Wang, W; Wu, K; Xu, T; Xu, X; Yuan, T, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Xu, X1
Wu, K1
Ma, X1
Wang, W1
Wang, H1
Huang, M1
Luo, L1
Su, C1
Yuan, T1
Shi, H1
Han, J1
Wang, A1
Xu, T1
Hill, MN1
Ho, WS1
Sinopoli, KJ1
Viau, V1
Hillard, CJ1
Gorzalka, BB1

Other Studies

2 other studies available for am 251 and Depressive Disorder, Major

ArticleYear
mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress.
    Molecular neurobiology, 2021, Volume: 58, Issue:10

    Topics: Animals; Cannabinoid Receptor Antagonists; Chronic Disease; Depressive Disorder, Major; Endocannabin

2021
Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2006, Volume: 31, Issue:12

    Topics: Animals; Antidepressive Agents, Tricyclic; Cannabinoid Receptor Modulators; Cortisone; Depressive Di

2006